Octagon Capital Advisors LP Grows Stock Position in Dianthus Therapeutics, Inc. $DNTH

Key Points

• Octagon Capital Advisors LP increased its stake in Dianthus Therapeutics by 11%, owning approximately 2.34 million shares worth about $42.48 million.
• Several institutional investors, including MIRAE ASSET GLOBAL and RA Capital Management, have also increased their positions in Dianthus Therapeutics, indicating strong interest among large investors.
• Analysts generally rate Dianthus Therapeutics as a "Buy," with an average target price of $54, despite recent earnings that missed consensus estimates.

Octagon Capital Advisors LP grew its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 11.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,341,667 shares of the company's stock after purchasing an additional 231,500 shares during the period. Dianthus Therapeutics comprises about 4.5% of Octagon Capital Advisors LP's holdings, making the stock its 4th largest holding. Octagon Capital Advisors LP owned approximately 7.29% of Dianthus Therapeutics worth $42,478,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. US Bancorp DE lifted its stake in Dianthus Therapeutics by 2,013.3% during the first quarter. US Bancorp DE now owns 1,585 shares of the company's stock worth $29,000 after purchasing an additional 1,510 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at about $59,000. GAMMA Investing LLC lifted its stake in shares of Dianthus Therapeutics by 3,030.6% in the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock valued at $70,000 after acquiring an additional 3,758 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Dianthus Therapeutics by 21.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,468 shares of the company's stock valued at $207,000 after acquiring an additional 1,647 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Dianthus Therapeutics by 4.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock valued at $280,000 after acquiring an additional 618 shares during the last quarter. Institutional investors own 47.53% of the company's stock.

Wall Street Analysts Forecast Growth

DNTH has been the subject of a number of recent research reports. Wedbush boosted their target price on Dianthus Therapeutics from $42.00 to $44.00 and gave the company an "outperform" rating in a research note on Friday. Guggenheim boosted their target price on Dianthus Therapeutics from $92.00 to $100.00 and gave the company a "buy" rating in a research note on Tuesday, September 9th. HC Wainwright restated a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday, September 8th. William Blair began coverage on Dianthus Therapeutics in a report on Wednesday, July 2nd. They set an "outperform" rating on the stock. Finally, Raymond James Financial restated an "outperform" rating and set a $63.00 price target (up previously from $56.00) on shares of Dianthus Therapeutics in a report on Tuesday, September 9th. Nine research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $61.57.

Insider Activity at Dianthus Therapeutics

In related news, CFO Ryan Savitz sold 20,000 shares of the company's stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total value of $700,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 16.56% of the stock is currently owned by corporate insiders.

Dianthus Therapeutics Trading Down 1.8%

Shares of DNTH stock traded down $0.70 during midday trading on Friday, reaching $37.16. 996,987 shares of the stock were exchanged, compared to its average volume of 948,551. Dianthus Therapeutics, Inc. has a 1 year low of $13.36 and a 1 year high of $38.59. The company's 50 day moving average is $23.01 and its two-hundred day moving average is $20.53. The firm has a market cap of $1.20 billion, a PE ratio of -11.43 and a beta of 1.46.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.87 million. As a group, equities analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.